The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Targeting nuclear receptors for the treatment of fatty liver disease
Open accessAbstract
ABSTRACT Ligand‐activated nuclear receptors, including peroxisome proliferator‐activated receptor alpha (PPAR&agr;), pregnane X receptor, and constitutive androstane receptor, were first identified as key regulators of the responses against chemical toxicants. However, numerous studies using mouse disease models and human samples have revealed critical roles for these receptors and others, such as PPAR&bgr;/&dgr;, PPAR&ggr;, farnesoid X receptor (FXR), and liver X receptor (LXR), in maintaining nutrient/energy homeostasis in part through modulation of the gut‐liver‐adipose axis. Recently, disorders associated with disrupted nutrient/energy homeostasis, e.g., obesity, metabolic syndrome, and non‐alcoholic fatty liver disease (NAFLD), are increasing worldwide. Notably, in NAFLD, a progressive subtype exists, designated as non‐alcoholic steatohepatitis (NASH) that is characterized by typical histological features resembling alcoholic steatohepatitis (ASH), and NASH/ASH are recognized as major causes of hepatitis virus‐unrelated liver cirrhosis and hepatocellular carcinoma. Since hepatic steatosis is basically caused by an imbalance between fat/energy influx and utilization, abnormal signaling of these nuclear receptors contribute to the pathogenesis of fatty liver disease. Standard therapeutic interventions have not been fully established for fatty liver disease, but some new agents that activate or inhibit nuclear receptor signaling have shown promise as possible therapeutic targets. In this review, we summarize recent findings on the roles of nuclear receptors in fatty liver disease and discuss future perspectives to develop promising pharmacological strategies targeting nuclear receptors for NAFLD/NASH.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519 · cited 1×
“To explain a mechanism of rapid and drastic changes following PP administration, the involvement of transcription factors was assumed and the first PPAR [later defined as PPARα (NR1C1)] was identified in 1990 (Issemann & Green, 1990).”
BackgroundNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · cited 1×
“Others reported that the survival of NASH patients, but not NAFL patients, was significantly lower than an age- and sex-matched reference population (Ekstedt et al., 2006).”
BackgroundFGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Human Fatty Liver Disease: Old Questions and New Insights
Cohen, J. C., Horton, J. D., & Hobbs, H. H. (2011) · Science · doi:10.1126/science.1204265 · Cited by 2,089
PPARγ signaling and metabolism: the good, the bad and the future
Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., & Evans, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3159 · Cited by 2,016 · cited 2×
“PPARγ is highly expressed in adipose tissue and macrophage where it has an important role in energy storage and immune modulation, respectively (Ahmadian et al., 2013).”
BackgroundPeroxisome proliferator–activated receptor α mediates the adaptive response to fasting
Kersten, S., Seydoux, J., Peters, J. M., Gonzalez, F. J., Desvergne, B., & Wahli, W. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6223 · Cited by 1,649
Self-citationInagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Nuclear Receptors, RXR, and the Big Bang
Evans, R. M., & Mangelsdorf, D. J. (2014) · Cell · doi:10.1016/j.cell.2014.03.012 · Cited by 1,200
Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor
Inagaki, T., Moschetta, A., Lee, Y.-K., Peng, L., Zhao, G., Downes, M., Yu, R. T., Shelton, J. M., Richardson, J. A., Repa, J. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509592103 · Cited by 1,164 · cited 1×
“FXR activation by GW4064 and CDCA promoted the expression of several genes that have antimicrobial properties, inhibited NF-κB expression, and reduced pro-inflammatory cytokines (Inagaki et al., 2006).”
BackgroundDelerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Self-citationRatziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · cited 1×
“Considering weak effects of PPARβ/δ activators on hepatic steatosis and fibrosis, a dual PPARα/β activator, elafibranor, has been developedwhich showed beneficial effects for human NASH (Ratziu et al., 2016).”
BackgroundCusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · cited 1×
“…pioglitazone treatment achieved higher NASH histological improvement rate and resolution rate with statistically significant improvement in steatosis, inflammation and ballooning, as well as correction of insulin resistance and hypoadiponectinemia, compared with placebo (Cusi et al., 2016).”
BackgroundBeyond insulin resistance in NASH: TNF-α or adiponectin?
Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942
The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes
Gaich, G., Chien, J. Y., Fu, H., Glass, L. C., Deeg, M. A., Holland, W. L., Kharitonenkov, A., Bumol, T., Schilske, H. K., & Moller, D. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.08.005 · Cited by 885 · cited 2×
“, 2005, 2007), and improves serum lipid profiles in obese humans with type 2 diabetes (Gaich et al., 2013).”
BackgroundIdentification of a novel FGF, FGF-21, preferentially expressed in the liver
Nishimura, T., Nakatake, Y., Konishi, M., & Itoh, N. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00067-1 · Cited by 847
Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 1×
“Obeticholic acid (OCA, also known as INT-747), a 6α-ethyl derivative of chenodeoxycholic acid (CDCA), is the first-in-class selective FXR agonist that is approximately 100-fold potent than CDCA for FXR activation (Pellicciari et al., 2002).”
BackgroundIntestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76738 · Cited by 693
Self-citationRatziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · cited 1×
“The usefulness of rosiglitazone for human NASH was evaluated in the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) trial in 2008 (Ratziu et al., 2008).”
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559
Self-citationCircadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis
Kettner, N. M., Voicu, H., Finegold, M. J., Coarfa, C., Sreekumar, A., Putluri, N., Katchy, C. A., Lee, C., Moore, D. D., & Fu, L. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.007 · Cited by 508 · cited 1×
“CAR activation promoted hepatocarcinogenesis and loss of CAR inhibited NAFLD/NASH-induced HCC in mice (Kettner et al., 2016; Takizawa et al., 2011).”
BackgroundYang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488 · cited 1×
“Fxr-null mice develop BA overload and spontaneous HCC by the age of 12–16 months (Kim et al., 2007; Yang et al., 2007).”
BackgroundPeroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Wei, W., Dutchak, P. A., Wang, X., Ding, X., Wang, X., Bookout, A. L., Goetz, R., Mohammadi, M., Gerard, R. D., Dechow, P. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200797109 · Cited by 426 · cited 1×
“A deleterious bone loss caused by PPARγ agonists was prevented in Fgf21-null mice, and Fgf21 transgenic mice and repeated recombinant FGF21-injected mice demonstratedmarked trabecular bone loss (Wei et al., 2012).”
BackgroundSpontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl249 · Cited by 357 · cited 1×
“Fxr-null mice develop BA overload and spontaneous HCC by the age of 12–16 months (Kim et al., 2007; Yang et al., 2007).”
BackgroundSelf-citationZhu, X., Owen, J. S., Wilson, M. D., Li, H., Griffiths, G. L., Thomas, M. J., Hiltbold, E. M., Fessler, M. B., & Parks, J. S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m006486 · Cited by 331
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Gomez-Ospina, N., Potter, C. J., Xiao, R., Manickam, K., Kim, M.-S., Kim, K. H., Shneider, B. L., Picarsic, J. L., Jacobson, T. A., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10713 · Cited by 300
Adiponectin, driver or passenger on the road to insulin sensitivity?
Ye, R., & Scherer, P. E. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.04.001 · Cited by 251 · cited 2×
“Circulating adiponectin enhances glucose uptake in peripheral tissues and FA βoxidation in hepatocytes through activation of AMPK, attenuating hepatic steatosis and improving systemic insulin sensitivity (Ye & Scherer, 2013).”
BackgroundNagasawa, T., Inada, Y., Nakano, S., Tamura, T., Takahashi, T., Maruyama, K., Yamazaki, Y., Kuroda, J., & Shibata, N. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.02.028 · Cited by 233 · cited 1×
“GW501516 attenuated NASH in MCD diet-treated mice by down-regulating TNFα and MCP1 expression (Nagasawa et al., 2006).”
BackgroundYe, D., Wang, Y., Li, H., Jia, W., Man, K., Lo, C. M., Wang, Y., Lam, K. S. L., & Xu, A. (2014) · Hepatology · doi:10.1002/hep.27060 · Cited by 184 · cited 2×
“Acetaminophen overdose-induced liver injury and mortality were significantly aggravated in Fgf21-null mice compared with wild-type mice, likely due to impaired PPARγ coactivator 1α (PGC1α)-nuclear factor erythroid 2-related factor 2 (NRF2)-mediated antioxidant capacity and increased oxidative stress, and acetaminophen…”
BackgroundProtection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met
Tomita, K., Azuma, T., Kitamura, N., Nishida, J., Tamiya, G., Oka, A., Inokuchi, S., Nishimura, T., Suematsu, M., & Ishii, H. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.12.008 · Cited by 141
Narala, V. R., Adapala, R. K., Suresh, M. V., Brock, T. G., Peters-Golden, M., & Reddy, R. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.085118 · Cited by 126 · cited 4×
“Long-chain FAs and eicosanoids are typical endogenous ligands for PPARα and PPARβ/δ (Narala et al., 2010; Yu et al., 1995), while PPARγ is specifically activated by arachidonic acid metabolites belonging to 5-hydroxyeicosatetraenoic acid family, such as 5-oxo-15(S)-hydroxyeicosatetraenoic acid and…”
BackgroundInfluentialShan, W., Palkar, P. S., Murray, I. A., McDevitt, E. I., Kennett, M. J., Kang, B. H., Isom, H. C., Perdew, G. H., Gonzalez, F. J., & Peters, J. M. (2008) · Toxicological Sciences · doi:10.1093/toxsci/kfn142 · Cited by 97
Self-citationThe LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
Griffett, K., Welch, R. D., Flaveny, C. A., Kolar, G. R., Neuschwander-Tetri, B. A., & Burris, T. P. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.01.009 · Cited by 95
Brocker, C. N., Yue, J., Kim, D., Qu, A., Bonzo, J. A., & Gonzalez, F. J. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00205.2016 · Cited by 93 · cited 2×
“creases in plasma ketone bodies and FGF21 in a fasting state, similarly to Ppara-null mice (Brocker et al., 2017; Montagner et al., 2016).”
BackgroundSelf-citationMAREK, C. J., TUCKER, S. J., KONSTANTINOU, D. K., ELRICK, L. J., HAEFNER, D., SIGALAS, C., MURRAY, G. I., GOODWIN, B., & WRIGHT, M. C. (2005) · Biochemical Journal · doi:10.1042/bj20041598 · Cited by 89
Kostadinova, R., Montagner, A., Gouranton, E., Fleury, S., Guillou, H., Dombrowicz, D., Desreumaux, P., & Wahli, W. (2012) · Cell & Bioscience · doi:10.1186/2045-3701-2-34 · Cited by 83
Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.6466 · Cited by 83
Beilke, L. D., Aleksunes, L. M., Holland, R. D., Besselsen, D. G., Beger, R. D., Klaassen, C. D., & Cherrington, N. J. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023317 · Cited by 73 · cited 1×
“CAR protects against toxic food contaminants or metabolites (Beilke et al., 2009; Uppal et al., 2005).”
BackgroundFGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists
Li, X., Stanislaus, S., Asuncion, F., Niu, Q.-T., Chinookoswong, N., Villasenor, K., Wang, J., Wong, P., Boyce, R., Dwyer, D., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2936 · Cited by 61 · cited 1×
“4), it remains elusive because of the presence of contradicting results (Li et al., 2017).”
BackgroundSartor, R. B. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13436 · Cited by 60 · cited 2×
“Rifaximin was proposed as a treatment for Crohn's disease (Sartor, 2016), and was approved for the treatment of irritable bowel syndrome, a milder form of IBD (Lucak,”
Background
Cited by
Triggering and resolution of inflammation in NASH
Schuster, S., Cabrera, D., Arrese, M., & Feldstein, A. E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0009-6 · Cited by 943
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice
Wang, Y., Nakajima, T., Gonzalez, F. J., & Tanaka, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062061 · Cited by 540
Self-citationBile acids in glucose metabolism and insulin signalling — mechanisms and research needs
Ahmad, T. R., & Haeusler, R. A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0266-7 · Cited by 337
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets
Chen, H., Tan, H., Wan, J., Zeng, Y., Wang, J., Wang, H., & Lu, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108391 · Cited by 311
Metadata
- Authors
- Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 179
- Pages
- 142-157
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2618863496
- Cited by
- 212
- References
- 48
- FWCI
- 18.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.